Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.76
+$0.23 · +15.03%
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Previous close
$1.76
+$0.23 · +15.03%
After-hours
$1.7139
−$0.0461 · -2.62%
Sep 4, 7:57 PM ET
Regular session · ET · Market data may be delayed.
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Day range
Current $1.76
52-week range
Current $1.76
Regular session · ET · Market data may be delayed.
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Day range
Current $1.76
52-week range
Current $1.76
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
